MediWound (NASDAQ:MDWD) Stock Crosses Below 200-Day Moving Average - Time to Sell?

Shares of MediWound Ltd. (NASDAQ:MDWD - Get Free Report) passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $17.45 and traded as low as $14.77. MediWound shares last traded at $15.35, with a volume of 130,738 shares.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on MDWD. StockNews.com raised MediWound to a "sell" rating in a research report on Friday, March 21st. Craig Hallum started coverage on shares of MediWound in a research note on Friday, February 28th. They issued a "buy" rating and a $39.00 target price for the company. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $25.00 target price on shares of MediWound in a report on Thursday, March 20th.

MediWound Price Performance

The company has a market cap of $176.99 million, a PE ratio of -5.65 and a beta of 0.50. The firm has a 50-day simple moving average of $17.12 and a two-hundred day simple moving average of $17.42.

MediWound (NASDAQ:MDWD - Get Free Report) last posted its quarterly earnings data on Wednesday, March 19th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, beating analysts' consensus estimates of ($0.59) by $0.23. MediWound had a negative net margin of 142.29% and a negative return on equity of 82.17%. The business had revenue of $5.84 million during the quarter, compared to analyst estimates of $5.79 million. During the same quarter in the previous year, the business posted ($0.19) earnings per share. Equities research analysts forecast that MediWound Ltd. will post -2.66 EPS for the current year.

Remove Ads

Hedge Funds Weigh In On MediWound

Several institutional investors have recently added to or reduced their stakes in the business. Rhumbline Advisers increased its stake in shares of MediWound by 7.3% during the 4th quarter. Rhumbline Advisers now owns 10,835 shares of the biopharmaceutical company's stock valued at $193,000 after acquiring an additional 739 shares during the last quarter. Russell Investments Group Ltd. increased its position in MediWound by 154.1% during the fourth quarter. Russell Investments Group Ltd. now owns 1,916 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 1,162 shares during the last quarter. Barclays PLC raised its stake in MediWound by 11.2% during the fourth quarter. Barclays PLC now owns 12,412 shares of the biopharmaceutical company's stock worth $221,000 after purchasing an additional 1,249 shares during the period. GAMMA Investing LLC boosted its holdings in shares of MediWound by 1,507.1% in the 1st quarter. GAMMA Investing LLC now owns 1,816 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 1,703 shares during the last quarter. Finally, R Squared Ltd acquired a new stake in shares of MediWound during the 4th quarter worth $32,000. 46.83% of the stock is currently owned by institutional investors and hedge funds.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.